Muscles, tendons, fascia, nerves, fat, ligaments, blood vessels, and synovial membranes are examples of soft tissues which connect, encircle, and support other bodily organs and structures. They can be damaged by various physical activities, which can cause discomfort, sprains, strains, edema, bursitis, tendinitis, and contusions. Therefore, many corrective procedures are used to restore, fix, and regenerate soft tissues. For example, biomaterials for their repair include scaffolds consisting of natural polymers like chitosan, gelatin, and alginate. In addition, allografts and xenografts are growing in popularity for treating serious injuries worldwide.
The market for soft tissue repair in 2021 was USD 12.62 billion and will reach USD 22.84 billion by 2030 at a 6.81% CAGR.
Table of Contents
During this projection period, an increase in the incidence of obesity will drive the global market for soft tissue repair. Additionally, the expansion of the worldwide soft Tissue repair market will be driven by an increasing number of products being introduced and industry consolidation. For instance, the use of biological grafts is being promoted by important manufacturers. The market for these items is projected to increase because biological grafts have a shorter recovery time and fewer injection-related problems. Another factor fueling the soft tissue repair market is the rise in the number of patients experiencing sports-related injuries.
Physicians’ and surgeons’ lack of proper product knowledge and acceptance of biological products is anticipated to restrain the growth of the global soft tissue repair market. Lack of proper product knowledge may result in misuse and ineffective usage of items, harming patients or negatively affecting their health.
Orthopedic soft tissue repair market participants will find plenty of opportunities for growth in nations like China, India, and Brazil. Large patient populations for the targeted indications (cardiovascular and soft tissue repair patches, orthopedic, general/abdominal, and gynecological problems), growing health awareness, rising healthcare spending, increasing medical tourism, and rapidly developing healthcare infrastructure in these countries are all contributing factors.
In 2021, the tissue patch/matrix sector segment ruled the overall market and generated revenue of USD 6.779 million. It is due to soaring demand and growing knowledge of the advantages offered by tissue patch/matrix in soft tissue repair treatments. The usage of a hernia matrix may improve a patient’s prognosis since the repair process and recuperation may go faster than other therapy alternatives, according to the U.S. FDA.
On the basis of application, the orthopedic market held a sizeable market share in 2021 and will reach USD 5,776 million by 2030. This market segment is expanding due to growing demand and increased awareness of the significant benefits that tissue repair products offer in the treatment of various orthopedic conditions. The introduction of novel technologies such as biological meshes, bioprinting, and biomanufacturing to treat such diseases is expected to improve segment revenue.
End Use Insights
Based on end-use, hospitals held a commanding market share in 2021 and will reach USD 10,439 million by 2030. It is due to the rising use of novel tissue repair products in hospital settings, which will increase patient preference for these healthcare facilities and deliver quick and reliable results. Hospitals’ preferences for particular products are influenced by the wide range of technologically sophisticated tissue fixation devices available for carrying out these surgical procedures with confirmed precision.
In 2021, the U.S. had a sizable market share in North America and will surpass USD 7,242 million by 2030. Numerous elements, including the presence of prominent industry competitors and an increase in the need for tissue repair products, are responsible for the sizeable market share. The region’s industrial progress is made possible by the involvement of well-known companies like Zimmer Biomet, Stryker Corporation, and Arthrex, among others, in developing and commercializing innovative products.
Plastic operations heavily rely on soft tissue repair items like tissue patches and xenografts. In 2020, over 1.8 million surgical cosmetic treatments and 15.9 million minimally invasive cosmetic surgeries were performed in the United States, according to figures provided by the American Society of Plastic Surgeons (ASPS). Additionally, continual improvements in product development, rising healthcare costs, and the availability of facilities with modern surgical care equipment are all favorably influencing product demand.
- Arthrex, Inc. (U.S.)
- Smith & Nephew Plc. (U.K.)
- Johnson & Johnson (U.S.)
- Stryker Corporation (US)
- Medtronic Plc. (I.E.)
- Becton, Dickinson, and Company (U.S.)
- LifeNet Health, Inc. (U.S.)
- Integra LifeSciences Corporation (U.S.)
- Organogenesis Inc. (US)
- CryoLife, Inc. (U.S.)
- Zimmer Biomet (U.S.)
- ACell Inc. (U.S.)
- Baxter International, Inc. (U.S.)
- In2Bones (U.S.)
- Aroa Biosurgery Ltd. (N.Z.)
- Tissue Regenix Group Plc (U.K.)
- Orthofix Medical Inc.
The market for soft tissue repair in 2021 was USD 12.62 billion and will reach USD 22.84 billion by 2030 at a 6.81% CAGR. The presence of a significant patient population and the attention of market leaders on grabbing the opportunity in the soft tissue repair market is driving market expansion.